CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total net revenue	$ 125,072	$ 121,724	$ 242,241	$ 237,257
COST OF REVENUE	81,126	68,734	160,063	142,693
GROSS PROFIT	43,946	52,990	82,178	94,564
Operating expenses:
General and administrative	57,951	54,638	124,199	95,114
Research and development	8,626	3,495	16,339	5,951
Sales and marketing	17,071	17,224	33,370	30,973
Total operating expenses	83,648	75,357	173,908	132,038
Loss from operations	(39,702)	(22,367)	(91,730)	(37,474)
Interest expense, net	926	902	2,227	2,079
Other expense (income), net	405	(171)	237	(341)
Gain on investment in and loan receivable from non-consolidated affiliate, net	0	(96,534)	0	(91,510)
(Loss) income before taxes	(41,033)	73,436	(94,194)	52,298
Income tax benefit	(5,730)	(2,437)	(9,483)	(1,461)
NET (LOSS) INCOME	$ (35,303)	$ 75,873	$ (84,711)	$ 53,759
NET (LOSS) INCOME PER SHARE
Basic (in dollars per share)	$ (0.28)	$ 0.64	$ (0.68)	$ 0.46
Diluted (in dollars per share)	$ (0.28)	$ 0.59	$ (0.68)	$ 0.44
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic (in shares)	124,068	118,287	123,850	117,249
Diluted (in shares)	124,068	131,237	123,850	130,247
Clinical Services
Total net revenue	$ 105,635	$ 101,405	$ 204,426	$ 197,892
COST OF REVENUE	67,035	57,233	132,302	118,798
GROSS PROFIT	38,600	44,172	72,124	79,094
Pharma Services
Total net revenue	19,437	20,319	37,815	39,365
COST OF REVENUE	14,091	11,501	27,761	23,895
GROSS PROFIT	$ 5,346	$ 8,818	$ 10,054	$ 15,470